Head-to-head evidence
Neratinib vs STX-721
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR/HER2 · full Non-Small Cell Lung Cancer pipeline
Neratinib
Marketed by Puma Biotechnology
NCT06029816 · Phase 2 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
STX-721
Developed by Pierre Fabre Medicament
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2029 · NCT06043817 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Neratinib's landscape · STX-721's landscape